Michael F. Cola - 11 Jun 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
Brandon Marsh, as Attorney-in-Fact for Michael F Cola
Issuer symbol
SAGE
Transactions as of
11 Jun 2025
Transactions value $
$0
Form type
4
Filing time
13 Jun 2025, 16:13:36 UTC
Previous filing
05 Jun 2025
Next filing
31 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
COLA MICHAEL F Director C/O SAGE THERAPEUTICS, INC., 55 CAMBRIDGE PARKWAY, CAMBRIDGE Brandon Marsh, as Attorney-in-Fact for Michael F Cola 13 Jun 2025 0001188940

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +21.5K $0.00 21.5K 11 Jun 2025 Common Stock 21.5K $6.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.